Raymond James & Associates Cerus Corp Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

A detailed history of Raymond James & Associates transactions in Cerus Corp stock. As of the latest transaction made, Raymond James & Associates holds 307,120 shares of CERS stock, worth $605,026. This represents 0.0% of its overall portfolio holdings.

Number of Shares
307,120
Previous 307,220 0.03%
Holding current value
$605,026
Previous $540,000 1.11%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024
SELL
$1.7 - $2.39 $170 - $239
-100 Reduced 0.03%
307,120 $534,000
Q2 2024

Jul 19, 2024
SELL
$1.62 - $2.04 $13,446 - $16,932
-8,300 Reduced 2.63%
307,220 $540,000
Q1 2024

Apr 22, 2024
SELL
$1.66 - $2.42 $77,605 - $113,135
-46,750 Reduced 12.9%
315,520 $596,000
Q4 2023

Jan 16, 2024
SELL
$1.25 - $2.35 $402,946 - $757,538
-322,357 Reduced 47.09%
362,270 $782,000
Q3 2023

Oct 24, 2023
SELL
$1.5 - $3.07 $398,227 - $815,038
-265,485 Reduced 27.94%
684,627 $1.11 Million
Q2 2023

Jul 25, 2023
SELL
$1.79 - $2.9 $254,199 - $411,831
-142,011 Reduced 13.0%
950,112 $2.34 Million
Q1 2023

Apr 14, 2023
SELL
$2.65 - $3.81 $269,462 - $387,416
-101,684 Reduced 8.52%
1,092,123 $3.24 Million
Q4 2022

Feb 08, 2023
SELL
$3.38 - $4.22 $227,812 - $284,428
-67,400 Reduced 5.34%
1,193,807 $4.36 Million
Q3 2022

Oct 25, 2022
SELL
$3.43 - $5.83 $15,435 - $26,235
-4,500 Reduced 0.36%
1,261,207 $4.54 Million
Q2 2022

Aug 12, 2022
SELL
$4.41 - $5.69 $45,643 - $58,891
-10,350 Reduced 0.81%
1,265,707 $6.7 Million
Q1 2022

May 11, 2022
BUY
$4.81 - $6.99 $15,872 - $23,067
3,300 Added 0.26%
1,276,057 $7.01 Million
Q4 2021

Feb 08, 2022
SELL
$5.97 - $7.93 $120,594 - $160,186
-20,200 Reduced 1.56%
1,272,757 $8.67 Million
Q3 2021

Nov 02, 2021
SELL
$4.79 - $6.68 $51,732 - $72,144
-10,800 Reduced 0.83%
1,292,957 $7.87 Million
Q2 2021

Aug 11, 2021
BUY
$5.35 - $6.35 $27,017 - $32,067
5,050 Added 0.39%
1,303,757 $7.71 Million
Q1 2021

May 14, 2021
BUY
$5.68 - $7.87 $450,895 - $624,744
79,383 Added 6.51%
1,298,707 $7.81 Million
Q4 2020

Feb 12, 2021
BUY
$5.25 - $8.56 $127,706 - $208,222
24,325 Added 2.04%
1,219,324 $8.44 Million
Q3 2020

Nov 04, 2020
BUY
$5.78 - $7.47 $24,755 - $31,994
4,283 Added 0.36%
1,194,999 $7.48 Million
Q2 2020

Jul 28, 2020
SELL
$4.5 - $7.02 $157,275 - $245,348
-34,950 Reduced 2.85%
1,190,716 $7.86 Million
Q1 2020

Apr 21, 2020
BUY
$2.87 - $5.49 $281,842 - $539,134
98,203 Added 8.71%
1,225,666 $5.7 Million
Q4 2019

Feb 12, 2020
BUY
$3.84 - $4.86 $92,640 - $117,247
24,125 Added 2.19%
1,127,463 $4.76 Million
Q3 2019

Nov 07, 2019
BUY
$4.86 - $6.05 $55,452 - $69,030
11,410 Added 1.04%
1,103,338 $5.69 Million
Q2 2019

Aug 06, 2019
BUY
$4.51 - $6.6 $475,344 - $695,626
105,398 Added 10.68%
1,091,928 $6.14 Million
Q1 2019

May 06, 2019
SELL
$5.16 - $6.85 $93,912 - $124,670
-18,200 Reduced 1.81%
986,530 $6.15 Million
Q4 2018

Feb 11, 2019
BUY
$4.89 - $7.16 $454,672 - $665,736
92,980 Added 10.2%
1,004,730 $5.09 Million
Q3 2018

Nov 14, 2018
BUY
$6.89 - $7.78 $412,400 - $465,671
59,855 Added 7.03%
911,750 $6.57 Million
Q2 2018

Aug 14, 2018
BUY
$5.19 - $7.25 $185,283 - $258,825
35,700 Added 4.37%
851,895 $5.68 Million
Q1 2018

May 14, 2018
BUY
$3.56 - $5.74 $964 - $1,555
271 Added 0.03%
816,195 $4.47 Million
Q4 2017

Feb 14, 2018
SELL
$2.76 - $3.95 $57,435 - $82,199
-20,810 Reduced 2.49%
815,924 $2.76 Million
Q3 2017

Nov 13, 2017
BUY
$2.22 - $2.73 $7,326 - $9,009
3,300 Added 0.4%
836,734 $2.28 Million
Q2 2017

Aug 14, 2017
BUY
N/A
833,434
833,434 $2.09 Million

Others Institutions Holding CERS

# of Institutions
157
Shares Held
148M
Call Options Held
84.2K
Put Options Held
55.5K
View Full List

About CERUS CORP

CERS Quotes by TradingView
  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $349M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email